Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lintuzumab-Ac225 with Venetoclax and Azacitidine in R/R AML
NCT03932318Phase 2Withdrawn
- Sponsor
- Actinium Pharmaceuticals, Inc.
- Start
- Mar 2023
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of lintuzumab satetraxetan ac-225 in acute myeloid leukemia (AML), sponsored by Actinium Pharmaceuticals, Inc. Primary endpoints: Maximum Tolerated Dose and Overall Response Rate up to 6 months. Planned start Mar 2023; status: withdrawn.
02
Drugs
lintuzumab satetraxetan ac-225
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03932318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03932318.